Jinling Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jinling Pharmaceutical Company Limited with three other
companies in this sector in China:
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
sales of 3.18 billion Chinese Renmimbi [US$459.62 million]
of which 53%
was Medicine Manufacturing),
Heilongjiang ZBD Pharmaceutical Co Ltd
(3.14 billion Chinese Renmimbi [US$453.64 million]
of which 62%
was Pharmaceutical Industry), and
Guangdong Taiantang Pharmaceutical Co Ltd
(3.23 billion Chinese Renmimbi [US$467.06 million]
of which 49%
was Medicine Wholesale & Retail).
Jinling Pharmaceutical Company Limited reported sales of 3.19 billion Chinese Renmimbi (US$460.99 million)
December of 2017.
decrease of 10.8%
versus 2016, when the company's sales were 3.58 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 23.2% decline
in Other, from 122.67 million Chinese Renmimbi to 94.17 million Chinese Renmimbi.
There were also decreases in sales in
Medicine Manufacturing (down 17.6% to 2.16 billion Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Medical Service (up 12.3% to 935.63 million Chinese Renmimbi)